SU2C LUNG CANCER EARLY DETECTION CHALLENGE GRANTS: ROUND 1
PROGRAM GUIDELINES AND APPLICATION INSTRUCTIONS

About Stand Up To Cancer

Stand Up To Cancer® (SU2C) raises awareness and funds research to detect and treat cancers with the aspiration to cure all patients. SU2C is a 501(c)(3) charitable organization and was initially launched as a division of the Entertainment Industry Foundation. Established in 2008 by media and entertainment leaders, SU2C utilizes these communities' resources to engage the public in supporting a new, collaborative model of cancer research, to increase awareness about cancer prevention, and to highlight progress being made in the fight against the disease. As of April 2025, more than 3,100 scientists representing more than 210 institutions are involved in SU2C-funded research projects.

The American Association for Cancer Research (AACR) is SU2C's scientific partner. A Scientific Advisory Committee, led by William G. Nelson, M.D., Ph.D., conducts rigorous competitive review processes to identify the best research proposals to recommend for funding, oversee grants administration, and provide expert review of research progress.

Current members of the SU2C Founders and Advisors Committee (FAC) include Katie Couric, Sherry Lansing, Kathleen Lobb, Lisa Paulsen, Rusty Robertson, Sue Schwartz, Pamela Oas Williams, and Ellen Ziffren. The late Laura Ziskin and the late Noreen Fraser are also co-founders. Julian Adams, Ph.D., serves as SU2C's president and CEO.

For more information visit StandUpToCancer.org, Instagram, TikTok, X, Facebook, and YouTube.

SU2C COMMITMENT STATEMENT

SU2C is committed to reducing the burden of cancer through state-of-the-art approaches to prevention, screening, diagnosis, and treatment. Disparities in cancer persist, and mounting evidence demonstrates the need to develop precision prevention, interception, and treatment solutions for all populations. SU2C is committed to improving human health through biomedical research and addressing disparities through building relationships and partnerships with multiple stakeholders to develop and support research studies, including clinical trials, which will yield measurable outcomes for all.

PROGRAM MISSION STATEMENT

SU2C is interested in evaluating different platforms for liquid biopsies for the early detection of lung cancer. The National Lung Cancer Screening Trial (NLST) has established the current standard of low-dose CT scan (LDCT) in 20 pack-year smokers aged 50 and older. While this approach demonstrates a benefit in terms of the relative number of lives saved, it is unfortunately poorly adopted in the US. Furthermore, for those undergoing this screening test, the recidivism rate drops dramatically in subsequent years. The resulting integrated platform from this two-round program will detect early-stage lung cancers before treatment with drastic improvement in the existing standard and compliance.

RESEARCH PROJECT CRITERIA FOR ROUND 1

SU2C is soliciting applications for platforms to detect early-stage cancers (Stage 1 and 2) before treatment to improve patient outcomes in smokers. The applications should suggest modalities alternative to DNA-based and blood-based assays such as RNA in saliva, protein analytes in urine, and volatile organic compounds (VOCs) from breath. Assays from other bodily fluids will also be considered.

This program will be in two rounds. The following guidelines and application instructions are related to Round 1 only. Round 1 aims to determine the sensitivity and selectivity of each modality, as well as cost-effectiveness. The grant will range from $150-$200K and is intended to support a 12-month grant period. Applicants for Round 1 will either need access to banked samples which can be used for this research purpose or to budget for sample collection. The Round 1 grantee will be required to share data with the team selected for Round 2, as further described below, in which SU2C intends to apply machine learning to select the modalities that, when integrated in Round 2, offer the greatest promise.

In Round 2, the selected modalities will be included in a prospective clinical trial to produce a training set, from which an algorithm with the highest predictive outcome can be developed and validated. The algorithm seeks to improve on any single modality and to develop a paradigm for future screening that is both more accurate and cost-effective based on current standards, including LDCT and any single platform on its own. Funding for Round 2 may be in the form of a grant or impact investment from SU2C or a related impact investment fund established or sponsored by SU2C (the "SU2C Impact Fund").

ROUND 1 APPLICATION DEADLINE

The Full Application for Round 1 shall be submitted by Wednesday, December 2, 2026, at 11:59pm midnight Pacific Daylight Time. Teams invited to present at the virtual Selection Meeting will be informed on Wednesday, January 6, 2027. The Team Leader of the finalist teams will be required to present during the virtual Selection Meeting to be held on Monday, January 18, 2027. The selected team will be notified in February 2027 with anticipated project start dates in May 2027. See the section "Application Instructions" on page 8 for further information.

ROUND 1 TEAM COMPOSITION AND MEMBER ELIGIBILITY CRITERIA

The Team must include a Team Leader. Other potential team roles are defined below. No more than one additional Team Principal may be included, with a maximum of two participating institutions. Round 2 of this program will involve a comprehensive team with more required roles than in Round 1.

Definitions

1. **Team Leader (TL)** (required)**:** The Team Leader is the person responsible for the scientific and technical direction of the proposed research project, contractual and financial obligations, and other organizational assurances/certifications. The TL must ensure that the Team complies with the terms and conditions of the award and will be the primary contact person for SU2C science staff.
2. **Lead Institution** is the organization at which the Team Leader is employed, and it will be legally and financially responsible for the conduct of Team activities supported by the funds.
3. **Team Co-leader (TC):** A Team Co-leader is designated by the Team Leader to assist in directing the scientific and technical work of the Team. A Co-leader serves as an alternate contact person for SU2C science staff.
4. **Team Principal (TP):** Team Principal(s) is a senior investigator(s) who will lead a component(s)/subproject(s) of the Team research project.
5. **Project Manager:** The Team Project Manager (PM) is the administrative leader of the Team and the key administrative contact for the Team with SU2C. The PM is responsible for the coordination of all team efforts to consistently maintain a high level of functionality, collaboration, and communication. The PM coordinates the Patient Advocates and the scientific reporting, and, where appropriate, assists the Team in developing a plan for clinical trial accrual, diversity, and tracking.
6. **Patient Advocates:** Patient Advocates bring the perspectives of those affected by cancer (e.g., patients, survivors, caregivers) to the work of Team. They enable the Team scientists to see their research through the eyes of the target audience and integrate these perspectives into the direction of the Team research. Patient Advocate members do <u>not</u> represent the viewpoints or issues of any advocacy organization or their individual personal issues. Where appropriate, Patient Advocates also work with

the Team in developing a plan for clinical trial accrual, diversity, and tracking, including measures to ensure recruitment and retention of diverse participants. If you need assistance with the identification of qualified Patient Advocates for your application, you may contact proposals@su2c.org.

7. **Investigators:** Senior investigators, other than the TL, TC, and TPs, who are employed at the TL, TC, or TP institutions and contribute substantively to the Team research project, may be included as members of the Team.
8. **Early-Career Investigators:** Junior faculty (i.e. independent investigators who have completed their training no more than seven years prior to the start of the award term), postdoctoral fellows, clinical research fellows, or any other researchers-in-training who are working under the direction of a scientific mentor (i.e., a TL, TC, TP, or Investigator) may be included as members of the Team.
9. **Collaborator:** An Investigator who is not employed by a participating institution and is unfunded in this project budget yet makes valuable contributions to the Team.
10. **Budget and Contract contact** (required per institution)**:** For each participating institution/clinical trial site, provide at least two officials responsible for agreements.
11. **Other (Scientific/Technical):** Any person providing scientific or technical support, such as Lab managers and technicians
12. **Other (Administrative):** Any person providing administrative support such as administrative assistants
13. **Public Information Officer (PIO)** (required per institution)**:** The PIO is the communications coordinator or spokesperson for the institution.

Team Member Eligibility Requirements

1. Individuals on the FDA Debarment List may not apply.
2. Research is not restricted to the US. There are no citizenship or residency status restrictions for team members.
3. Eligibility requirements will be more extensive in Round 2.
4. There is no limit to the number of Investigators from each of the institutions that may contribute to the project.
5. Employees or subcontractors of for-profit industry are eligible.
6. Neither members of the SU2C Scientific Advisory Committee nor members of their individual laboratories are eligible for funding.

Applicants with a question about the eligibility requirements are encouraged to contact SU2C at proposals@su2c.org prior to submitting the proposal.

EVALUATION OF APPLICATIONS FOR ROUND 1

The Selection Committee will review the applications. The Selection Committee consists of highly accomplished experts who are respected internationally for their own accomplishments in cancer research and as leaders in the field.

The Selection Committee will consider the following criteria when evaluating the applications:

- Scientific merit of the proposed research project and translational potential of the research
- Significance of the proposed research
- Novelty of the hypothesis or methodology
- Degree to which the studies have a positive impact on the early-stage detection of lung cancer
- Team leadership qualities
- Involvement of patient advocates and/or community members in study design and implementation
- Alignment with the SU2C Commitment Statement
- Likelihood that the research project will achieve its stated goals given the budget requested, institutional environments, and other resources available

- Likelihood that patient enrollment to clinical trial(s) will be completed within the timeframe of the collaborative agreement
- Potential for broad dissemination, impact, and sustainability of the detection method
- Willingness to share data for the Round 2 project
- Whether adequate institutional and/or financial support exists to sustain the research project
- The cost effectiveness of the budget
- Evaluation criteria for Round 2 may be subject to such other additional investment and impact considerations as required by the SU2C Impact Fund, if applicable.

ROUND 1 TERMS

Changes to application. Applicants are not allowed to change the project nor the Team members proposed in the application. If changes are necessary, prior written approval from SU2C is required.

Contracts. A Collaborative Agreement will be executed between SU2C and the Team Leader's Institution, referred to as the Lead Institution. The Lead Institution must serve as the administrator of the funds and hold responsibility for the disbursement of the funds, management of the budget, and provision of progress and financial reports. It is expected that the Lead Institution will enter into subcontracts with the institutions of the Principal, which include all terms that are applicable to the Team Institution's or Team Member's performance of the project, and assurances that these contractual agreements have been executed will be required for continuation of funding.

Commencement. The Team Leader will commence upon execution of the contract agreement with the lead institution. Stand Up To Cancer retains the right to terminate the collaborative agreement if the research project is not commenced in a timely manner.

Budget. Teams may apply for total support up to $200,000 over a 12-month term. The templates provided with the application should be used to complete a detailed budget. SU2C strongly advises a limited 6-month budget as past Teams over-allocate funds in this timeframe. All funding is contingent upon: (1) milestones and deliverables being appropriately selected and satisfactorily pursued and achieved, as determined by SU2C, the SU2C Scientific Advisory Committee, the Selection Committee, and the Review Team; and (2) Lead Institution compliance with all applicable laws and financial accounting requirements.

Use of Funds. Funds may be used for direct research expenses attributable to the proposed research, which may include:

- Expenses related to the project and its implementation, including, for example, regulatory filings, sample collection and handling, database management, clinical coordinators, informed consent
- A percentage of the salary and benefits expenses (limited to 20 percent of the total budget) of senior investigators (NIH cap applies)
- A percentage of salary and benefits expenses of the Early Career Investigators on the Team
- Salary and benefits expenses for research assistants or technicians
- Equipment, supplies, and other laboratory or clinical expenses
- Travel expenses relevant to the Team research project, including travel to the institutions of the Team Leader/Principal and travel to meetings with the committees, as well as to the annual SU2C Scientific Summit
- Expenses (limited to a total of $5,000/year) related to publication page charges and/or the presentation of research data at scientific meetings or through other means that will contribute to the dissemination of the scientific knowledge derived from the proposed research

The funds may not be used for salary or benefits of any Collaborators from a government institution/agency or for any research expenses related to the Team project that are incurred by these individuals. Tuition and professional membership dues are not allowable expenses.

Any indirect costs charged by the institutions will be negotiated to a minimum, but in no event will there be permitted a charge of more than 10 percent of the total budget.

For applicants interested in working with the American Cancer Society for access to the samples available in their cohorts, please reach out to Dr. Alpa Patel at alpa.patel@cancer.org. Funds may be used for costs related to cohort access and use.

Payments. The payment schedule between the Team and Stand Up to Cancer will be delineated in the grant agreement.

Reporting Requirements. Progress and financial reports, submitted each year on July 15 and January 15, shall highlight the accomplishments of that specific time period bearing in mind the pre-defined Milestones and Deliverables of the Team. Progress Reports will be reviewed by SU2C and a Review Team drawn from the Selection Committee. The Team Leader and Co-Leader will be required to attend and present at biannual reviews: one annually in-person in January at the SU2C Scientific Summit and another virtually during the summer.

SU2C may withhold release of any or cancel future Funds until the reports have been filed and approved. Failure to address deficiencies, meet collaborative agreement requirements, or achieve the pre-defined Milestones and Deliverables may result in discontinuation of the funding.

Teams must meet three times a year, either in person, by teleconference, or by videoconference, to review progress and, if necessary, adjust research plans. Two of the required meetings can be fulfilled prior to the semi-annual reviews, where Team Leaders meet with the Review Team and all other Team members, following the submission of Progress Reports, to thoroughly discuss the Teams' progress. The review meeting schedule will be an appendix to the Team contract.

A final written progress and financial report shall be submitted no later than sixty (60) days after the ending date of the collaborative agreements term. The reporting materials must include all project components. The Team Leader may be asked to attend a follow-up meeting. The financial report shall document the expenditure of funds, the purpose of such expenditures, and how actual expenditures compared to the budget for the funding period.

SU2C may use all or portions of the report for public dissemination, such as within SU2C newsletters or websites, or in other similar manners, in consultation with the Team Leader.

Subject to Applicable Laws, and upon SU2C's reasonable request, Lead Institution agrees to provide access to SU2C or its designee to audit Lead Institution's financial books and records which are directly related to the Round 1 project.

The Lead Institution agrees that SU2C will be permitted sufficient access to monitor the progress of the Round 1 project at mutually agreeable times, including permitting any authorized SU2C staff member to monitor research on the Round 1 project at the Lead Institution or other site where research on the Round 1 project is being conducted.

Publications and Acknowledgment of Support. Any publications resulting from research funded in whole or in part by the agreement for Round 1 must cite SU2C in the acknowledgment: "Supported by a funds from Stand Up To Cancer." Copies of such publications shall be forwarded to SU2C after acceptance but before publication.

No external announcement, press release, or other public statement shall be made by Lead Institution, Team Institutions, or Team Members to publicize their involvement with SU2C, regardless of the medium used, without SU2C's prior written approval.

Lead Institution, Team Members, and Team Institutions must obtain SU2C's prior written approval for any use of the SU2C logos, trademarks, or service marks.

Intellectual Property. SU2C must be notified of any discovery that is protectable under applicable law (e.g. patentable) and is discovered in the course of the research funded under Round 1. Except as described in the paragraph immediately below, SU2C shall have no responsibility or interest in the protection of, commercialization, or licensing of intellectual property resulting from the Team in Round 1. The Team Leader and the Lead Institution shall notify SU2C of the granting of any patent or other legal protection and of all commercial exploitation of any invention in accordance with the terms of the grant agreement. Round 2 funding will be conditioned on the Round 1 team granting an interest to SU2C and/or the SU2C Impact Fund, as applicable, in the commercialization and/or other exploitation of any intellectual property result from Round 2 research. Terms and conditions regarding the protection of, commercialization, and/or licensing of such Round 2 intellectual property and SU2C and/or SU2C Impact Fund's interest therein will be set forth in the definitive Round 2 funding agreements, which may include, but not be limited to conditions requiring the exercise of commercially reasonable efforts to develop commercial products and services that exploit the intellectual property.

Round 1 Data and Intellectual Property. The Lead Institution and Team Leader will make the results and underlying data and any intellectual property arising from the Round 1 activities available to the Round 2 Lead Institution(s) for research and other purposes, including commercial purposes.

Lead Institution shall prepare and maintain complete, appropriate, and accurate written records, accounts, notes, laboratory notebooks, reports, and data to properly document the results of the Round 1 project. Case Report Forms and the electronic database (if applicable) shall be the exclusive property of Lead Institution. Lead Institution will retain in a safe and secure location one copy of all printed and electronic project records, Medical Records and Study Data for the longer of (a) seven (7) years after the last marketing authorization for the study article has been approved or Company has discontinued research on the study article(s) or (b) such longer period as required by FDA and any other applicable governmental requirements. Lead Institution shall not destroy any project documents without the prior written consent of SU2C.

The Lead Institution and Team Leader shall ensure the prompt, complete, and accurate collection, recording and classification of the Study Data and Medical Records. The Lead Institution and Subcontractors engaged by the Lead Institution shall:

1. Maintain and store Study Data and Medical Records in a secure manner with physical and electronic access restrictions, and environmental controls appropriate to the applicable data type and in accordance with applicable laws, regulations and industry standards; and
2. Protect the Study Data and Medical Records from unauthorized use, access, duplication, disclosure, loss, and damage.
3. At the conclusion of the project, the Lead Institution and SU2C will determine whether there is a need to retain Study Data and Medical Records beyond the minimum requirements set forth above
4. and, if so, will determine the procedures and resources needed to provide for such additional retention.

The Lead Institution shall be responsible for coordination of any publication of research results or data related to the project. Any such publication shall be made on behalf of the Team. Other than as required above in the paragraph entitled Round 1 Data and Intellectual Property, Team data and results may be shared with other recipients of SU2C funded research projects upon execution of a confidentiality agreement. Publication of

results or data jointly by two or more Teams as appropriate is permitted, subject to the Scientific Advisory Committee's involvement. The Lead Institution and/or any individual Team Member(s) may use or publish data or results from the project without the prior consent of SU2C, provided, however, that the Lead Institution and/or such Team Member must notify SU2C in writing upon acceptance for publication. In addition, Lead Institution may use results and data for reasonable purposes consistent with its mission.

Ethical and Legal Requirements. The Lead Institution will certify that the Team Member(s) which it employs, and, to the best of its belief, all other Team Members are not presently debarred, suspended, proposed for debarment, declared ineligible, or voluntarily excluded from covered transactions by any government department or agency; have not, within the 4-year period preceding the effective date, been convicted of, or had a civil judgment rendered against them for: 1) Committing fraud or a criminal offense in connection with obtaining, attempting to obtain, or performing a public transaction or contract under a public transaction; 2) Violating an antitrust statute; 3) Embezzlement, theft, forgery, bribery, falsification or destruction of records; 4) Making false statements or receiving stolen property; 5) Are not presently indicted or otherwise criminally or civilly charged by a government entity with commission of any of the offenses enumerated above; and 6) Have not, within a three (3) year period preceding the Effective Date, had any public transaction terminated for cause or default.

Lead Institution, Team Institutions, and Team Members have an affirmative duty to protect all Grant Funds from misuse by ensuring the integrity of the project. This duty involves discouraging and addressing research misconduct, meaning fabrication, falsification, or plagiarism in proposing, performing, or reviewing research or in reporting research results. In furtherance of this responsibility, the Lead Institution shall, and shall contractually require each Team Institution to 1) Have written policies and procedures for addressing allegations of research misconduct; 2) Respond to each allegation of research misconduct in a thorough, competent, objective and fair manner; 3) Foster a research environment that promotes the responsible conduct of research, discourages misconduct, and deals promptly with allegations or evidence of possible misconduct; 4) Take all reasonable steps to protect the positions and reputations of good faith complainants, witnesses and committee members and protect them from retaliation; 5) Fully investigate all good faith allegations of misconduct and complete reasonably promptly such investigations by determining whether or not such misconduct occurred and imposing sanctions where appropriate; and 6) Preserve the confidentiality of any allegations of misconduct and subsequent investigation.

Within ten (10) days of a finding of misconduct against any Team Member, Lead Institution must file a report with pertinent details describing the misconduct's potential effects on the conduct of the project to SU2C. Notwithstanding any disciplinary action imposed by the institution involved, SU2C will consider the situation and take any action it deems appropriate, in its sole discretion, including termination of the Team Member's involvement or termination of the project.

Financial Conflicts of Interest. Lead Institution shall maintain and shall take reasonable steps to contractually obligate all Team Institutions to maintain an appropriate written, enforced policy on conflict of interest that complies with 42 C.F.R. Part 50, Subpart F (§§ 601-606). The Lead Institution shall require each Team Institution to inform its employees of the Team Institution's policy and the individual employee's reporting obligations.

Compliance with SU2C Policies. Applicants agree to comply with SU2C's policies on (1) Tobacco Industry Funding and Material Support and (2) Bullying and Harassment, which are included as downloads in ProposalCentral.

Insurance. Insurance shall be maintained by the Team Members and Institutions for professional liability and comprehensive general liability insurance, on an "occurrence" basis, against claims for "personal injury" liability, including bodily injury, death, or property damage liability. Such insurance shall be primary and noncontributory

with any other insurance carried by SU2C and shall provide appropriate waivers of subrogation against SU2C, and its directors, committee members, employees, affiliates, and agents.

Notification of Changes. The Team Leader is responsible for notifying SU2C immediately of any changes in the composition of the Team and changes in the position or institution of any of the Team Members. SU2C may not accept proposals to change the research project from that described in the application and may terminate the funds.

Post-award, Lead institution may rebudget funding within and between budget categories in order to meet unanticipated needs and to make other post-award changes, provided that the total budget amount does not change. Additionally, Lead Institution may restrict Teams Institutions' authority to make budget changes without its prior written approval. However, Lead Institution must obtain SU2C's prior written approval for any significant rebudgeting, which occurs when the direct costs allocated to a single budget category are increased or decreased by more than fifteen percent (15%) of the total budget period award. If SU2C's approval is required, it must be requested in advance of making such change.

Organizational Assurances. The Team Leader and Lead Institution are responsible for ensuring that organizational assurances/certifications from all Team Member Institutions are obtained.

For research involving human subjects, the appropriate Team Member(s) and U.S. Institution(s) shall certify that:

a. Prior to the initiation of human research, the proposed research project has been reviewed and approved in writing by an Institutional Review Board ("IRB") constituted in accordance with current regulations promulgated by the United States Department of Health and Human Services ("HHS") and registered with HHS.

b. The Team Member(s) shall secure a legally acceptable informed consent from all human subjects taking part in any research funded in whole or in part by SU2C in accordance with and to the extent required by current regulations promulgated by the United States Department of Health and Human Services and approved by HHS. IRB approval for human subjects research should be submitted to SU2C, and funds for human subjects research will not be released unless and until proof of all IRB certifications is received by SU2C. Prior IRB approval for another project cannot be substituted but can be officially amended to include the proposed project.

For research involving animals, the Institution(s) shall ensure compliance with applicable chapters of the Public Health Service Animal Welfare Policy, the NIH Manual for Grants and Contracts, and any and all requirements of the Institution concerning animal welfare. Certification by the Institution Animal Care and Use Committee (IACUC) or equivalent shall be documented by submitting a copy of the institutional letter of approval, which identifies the Team Member(s) responsible for the project, the Team research project title, SU2C as the funding agencies, and the date of approval, and is signed by the IACUC Chair or equivalent Institution official. Prior IACUC certification for another project cannot be substituted but can be officially amended to include the proposed project.

Team Members at non-U.S. institutions must adhere to ethical standards for the protection of human and animal subjects that are at least equivalent to U.S. standards and to the legal requirements of the country of origin. Certification of ethical standards review and approval should be documented by submitting a letter, which cites all relevant approval and license numbers and dates required by the country of origin. In the absence of an official ethical review board (or equivalent) or legal requirements, the Team Member(s) must agree in writing to adhere at minimum to the World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects.

APPLICATION INSTRUCTIONS

The Full Application shall be submitted on ProposalCentral by Wednesday, December 2, 2026, at 11:59pm Pacific Daylight Time. Teams invited to present at the virtual Selection Meeting will be informed on Wednesday, January 6, 2027. The Team Leader and Co-Leader of the finalist teams will be required to present during the virtual Selection Meeting to be held on January 18, 2027. The selected team will be notified in February 2027 with an anticipated project start date in May 2027.

The Full Application includes the following elements:

- Title Page
- Signatures Pages: Signature pages must be submitted for every Institution requesting SU2C funds through this grant application. The Team Leader, Team Principal, and Institutional Budget and Contract Contacts must be included in the Signature Pages.
- Lay Abstract (limited to 1/2 page)
- Scientific Abstract (limited to 1/2 page)
- Research Proposal – to be uploaded as an attachment (limited to 3 pages; include the following information) (Template on Proposal Central)
    - Background and Rationale
    - Specific Aims
    - Research Design and Methods
    - Statistical Plan
    - Sample Access
    - Projected Timeline and Milestones
    - Significance and Therapeutic Impact
    - Collaboration/Team Members
    - Data Sharing Plan
- Facilities – to be uploaded as an attachment (limited to 1 page per Institution)
- References – to be uploaded as an attachment (no page limit)
- Other Support
- Budget Justification: – to be uploaded as an attachment
    - Limited to three (3) pages per institution. Detailed justification of the separate budget requests for expenses related to the research components/subprojects conducted by the Team Leader and Team Principal is required for all items of the equipment costing over $1,000, and the need for personnel, supplies, and other items. Provide the names of individuals whose salaries will be supported by the grant funds and justify the amount of support requested. If requesting "Other Expenses," a thorough list of these expenses along with the justification is required.
- Milestones and Deliverables Timeline – to be uploaded as an attachment (Template on Proposal Central)
- Requested funding and required regulatory approvals per Specific Aim
- Budget (should not exceed $200,000 USD): See sections "Budget" and "Use of Funds" on page 4-5 for additional information.
    - Information required for ProposalCentral includes:
        - Total Budget per Year
        - Budget per Institution (complete for every institution)
        - Total Budget per Institution
- Team Roster: See section "Eligibility Criteria" on page 2-3 for additional information.
- CVs for Team Leadership– to be uploaded as an attachment (Team Leader, Team Principal; NIH Biosketch preferred but not required; no template is provided; do not exceed five (5) pages per individuals)
- Letters of Support – to be uploaded as an attachment
    - Letters from Leadership at each Institution/Company involved in the Team

Other Application Information
Teams are required to have a Team Leader. Projects should be planned for 12 months. The proposed budget should not exceed $200,000 US dollars total.

Application Submission
Full Applications will be submitted through the ProposalCentral portal (proposalcentral.com) using the instructions, fields, and templates provided there. An email will be sent to confirm receipt of your online submission.

Changes to the Application
Following the submission of an application, the Team Leader should notify SU2C in writing of (1) any changes of address, email, or phone number for any Team member, (2) any changes in institution for any Team member, or (3) withdrawal of the application for any reason.

NOTIFICATION
Teams invited to present at the virtual Selection Meeting will be informed on or before Wednesday, January 6, 2027. The selected team will be notified in February 2027 with anticipated project start dates in May 2027.

INQUIRIES
SU2C is administering this grant program. Inquiries about the program guidelines, eligibility requirements, and application materials can be directed to SU2C Science at: proposals@su2c.org

Virtual RFA discussion meetings will be held on Thursday, October 15, 2026, and Thursday, November 19, 2026. Contact proposals@su2c.org no later than Wednesday, October 14, 2026, or Wednesday, November 18, 2026, for respective meeting details.